tetano
Editor, Senior Moderator
Liver Int
. 2020 Jun 3.
doi: 10.1111/liv.14557. Online ahead of print.
Abnormal Liver Tests in Patients Hospitalized With Coronavirus Disease 2019: Should We Worry?
Magdalena Meszaros[SUP] 1 2 [/SUP], Lucy Meunier[SUP] 1 [/SUP], David Morquin[SUP] 3 [/SUP], Kada Klouche[SUP] 4 [/SUP], Pierre Fesler[SUP] 5 [/SUP], Emilie Malezieux[SUP] 1 [/SUP], Alain Makinson[SUP] 3 [/SUP], Vincent le Moing[SUP] 3 [/SUP], Jacques Reynes[SUP] 3 [/SUP], Georges-Philippe Pageaux[SUP] 1 [/SUP]
Affiliations
Abstract
While several studies from China have reported COVID-19-related liver injury, there are currently no data on liver dysfunction in hospitalized COVID-19 patients in Europe. The aim of this study was to describe the prevalence and predictive value of abnormal liver function in patients hospitalized with COVID-19. This was a retrospective cohort study of confirmed COVID-19 patients hospitalized in two referral hospitals in France. Clinical, biological, and radiological data were collected and analyzed. Two hundred and thirty-four patients confirmed to have COVID-19 by RT-PCR were included. Liver function was abnormal in 66.6% of patients on admission. In multivariate logistic regression, abnormal liver test on admission were associated with in-hospital aggravation (OR=4.1, 95%CI 1.5-10.8; p=0.004) and mortality (OR 3.3; 95% CI=1.04-10.5; p=0.04). This study of liver tests in a European COVID-19 population confirms a high prevalence of abnormal liver tests on admission that are predictive of severe disease course and higher in-hospital mortality.
Keywords: Abnormal liver tests; Coronavirus Disease 2019; In-hospital aggravation; In-hospital mortality; Prognosis; SARS-CoV-2.
This article is protected by copyright. All rights reserved.
. 2020 Jun 3.
doi: 10.1111/liv.14557. Online ahead of print.
Abnormal Liver Tests in Patients Hospitalized With Coronavirus Disease 2019: Should We Worry?
Magdalena Meszaros[SUP] 1 2 [/SUP], Lucy Meunier[SUP] 1 [/SUP], David Morquin[SUP] 3 [/SUP], Kada Klouche[SUP] 4 [/SUP], Pierre Fesler[SUP] 5 [/SUP], Emilie Malezieux[SUP] 1 [/SUP], Alain Makinson[SUP] 3 [/SUP], Vincent le Moing[SUP] 3 [/SUP], Jacques Reynes[SUP] 3 [/SUP], Georges-Philippe Pageaux[SUP] 1 [/SUP]
Affiliations
- PMID: 32495496
- DOI: 10.1111/liv.14557
Abstract
While several studies from China have reported COVID-19-related liver injury, there are currently no data on liver dysfunction in hospitalized COVID-19 patients in Europe. The aim of this study was to describe the prevalence and predictive value of abnormal liver function in patients hospitalized with COVID-19. This was a retrospective cohort study of confirmed COVID-19 patients hospitalized in two referral hospitals in France. Clinical, biological, and radiological data were collected and analyzed. Two hundred and thirty-four patients confirmed to have COVID-19 by RT-PCR were included. Liver function was abnormal in 66.6% of patients on admission. In multivariate logistic regression, abnormal liver test on admission were associated with in-hospital aggravation (OR=4.1, 95%CI 1.5-10.8; p=0.004) and mortality (OR 3.3; 95% CI=1.04-10.5; p=0.04). This study of liver tests in a European COVID-19 population confirms a high prevalence of abnormal liver tests on admission that are predictive of severe disease course and higher in-hospital mortality.
Keywords: Abnormal liver tests; Coronavirus Disease 2019; In-hospital aggravation; In-hospital mortality; Prognosis; SARS-CoV-2.
This article is protected by copyright. All rights reserved.